舌下神经刺激治疗阻塞性睡眠呼吸暂停合并神经肌肉疾病
本研究报道5例合并神经肌肉疾病(重症肌无力2例、肌营养不良、腓骨肌萎缩症、晚期多发性硬化)的阻塞性睡眠呼吸暂停患者接受舌下神经刺激治疗。术后呼吸暂停低通气指数从基线34.9降至8.5(p=0.03),Epworth嗜睡量表评分从13.1降至8.5(p=0.03),3个月和12个月设备依从性分别为8±1.1小时/晚和7.2±1.7小时/晚。作者认为舌下神经刺激对该组患者安全有效,但需前瞻性研究和更大样本支持。
要点
- 5例合并神经肌肉疾病的阻塞性睡眠呼吸暂停患者接受舌下神经刺激治疗。
- 呼吸暂停低通气指数从34.9降至8.5(p=0.03),6例中5例术后低于5。
- Epworth嗜睡量表评分从13.1降至8.5(p=0.03),最低氧饱和度呈上升趋势(p=0.84)。
核心结论
- 有限的发现表明舌下神经刺激对5例阻塞性睡眠呼吸暂停合并神经肌肉疾病患者是安全有效的治疗。
- 需要前瞻性研究和更大样本量来支持上述发现,并确认舌下神经刺激是否为该特殊患者人群的潜在治疗选择。
研究设计与样本
- 本研究呈现5例接受舌下神经刺激治疗的阻塞性睡眠呼吸暂停患者,其中重症肌无力2例、肌营养不良1例、腓骨肌萎缩症1例、晚期多发性硬化1例。
- 手术时患者平均年龄54±18.7岁,平均体重指数24.6±4.6 kg/m2。
主要发现
- 平均设备依从性3个月时为8±1.1小时/晚,12个月时为7.2±1.7小时/晚。
- 平均呼吸暂停低通气指数从术前基线34.9改善至8.5(p=0.03),6例中5例术后呼吸暂停低通气指数低于5。
- Epworth嗜睡量表评分术后显著改善,从13.1降至8.5(p=0.03)。
- 最低氧饱和度呈上升趋势,从75.5升至85.3(p=0.84)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文自述为有限的发现。
- 原文指出需要前瞻性研究和更大样本量来支持发现并确认舌下神经刺激是否为该患者人群的潜在治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hypoglossal nerve stimulation (HGNS) is an effective surgical treatment for many patients with moderate-to-severe obstructive sleep apnea (OSA) who are unable to tolerate continuous positive airway pressure. Patients with neuromuscular disorders (NMD) are particularly vulnerable to more complex sleep-related breathing disorders due to respiratory muscle weakness and the associated risk of hypoventilation. In this study, we present five patients with myasthenia gravis (n = 2), muscular dystrophy, Charcot-Marie-Tooth, and advanced multiple sclerosis who underwent HGNS therapy for OSA. At time of surgery, the mean patient age was 54 ± 18.7 years and mean BMI was 24.6 ± 4.6 kg/m2. Mean device adherence was 8 ± 1.1 h/night at three months and 7.2 ± 1.7 h/night at 12 months. Mean apnea-hypopnea index (AHI) improved significantly from preoperative baseline (34.9 to 8.5, p = 0.03) and 5/6 patients had a postoperative AHI <5. Epworth Sleepiness Scale scores significantly improved postoperatively (13.1-8.5, p = 0.03). Oxygen nadir trended upward (75.5-85.3, p = 0.84). Our limited findings demonstrate that HGNS was a safe and effective treatment for five patients with OSA and comorbid NMD. Prospective studies and larger sample sizes are warranted to support our findings and confirm whether HGNS is a potential therapeutic option for this unique patient population. Laryngoscope, 135:2631-2633, 2025.
引用
- Choi AY, Kaffenberger TM, Soose RJ, et al. Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea and Comorbid Neuromuscular Disorders. Laryngoscope. 2025. PMID: 39953924. doi:10.1002/lary.32050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。